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ABSTRACT
Objective. Population-based surveillance data from California and Georgia for
years 2004 through 2008 were linked to state death record files to determine
the all-cause death rate among 12,143 patients identified with sickle cell
disease (SCD).
Methods. All-cause death rates, by age, among these SCD patients were
compared with all-cause death rates among both African Americans and the
total population in the two states. All-cause death rates were also compared
with death rates for SCD derived from publicly available death records: the
compressed mortality files and multiple cause of death files.
Results. Of 12,143 patients identified with SCD, 615 patients died. The
all-cause mortality rate for the SCD population was lower than the all-cause
mortality rate among African Americans and similar to the total population
all-cause mortality rates from birth through age 4 years, but the rate was higher
among those with SCD than both the African American and total population
rates from ages 5 through 74 years. The count of deceased patients identified
by using population-based surveillance data (n5615) was more than twice as
high as the count identified in compressed mortality files using SCD as the
underlying cause of death alone (n5297).
Conclusion. Accurate assessment of all-cause mortality and age at death
requires long-term surveillance via population-based registries of patients with
accurately diagnosed SCD.
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Ongoing public health surveillance of sickle cell
disease (SCD) is critical to understanding its course
and outcomes. Such surveillance is vital for medical
management, clinical and translational research, new
therapy development, public health planning, and
patient, family, and provider education.
Multiple research studies have used data collected through limited surveillance activities to better
understand age at death for patients with SCD. Studies published in the 1970s showed a poor prognosis
for patients with SCD, with a median age at death of
approximately 14 years, high mortality in the first five
years of life, and only about 15% of deaths occurring
after age 30 years.1 Results from a 1978 study based
on a newborn screening cohort in Jamaica found that
13% of children with hemoglobin SS disease and 5%
of children with hemoglobin SC disease died in the
first two years of life.2 Follow-up studies in Jamaica
confirmed this observation and showed that only 25%
of deaths among those with SCD occurred in patients
older than 30 years of age.3
The Cooperative Study of Sickle Cell Disease, which
followed SCD patients in the United States from 1978
through 1988, reported patient survival in its academic
center cohort, with a median age at death of 48 years
for women and 42 years for men with hemoglobin SS
disease, and 68 years for women and 60 years for men
with hemoglobin SC disease.4 This study also reported
that 50% of hemoglobin SS disease deaths occurred
in patients older than 45 years of age. A 2001 study,
using excess mortality simulation of a Jamaican cohort,
predicted that 50% of SCD deaths would occur in those
older than 53 years of age.5 Additional studies based on
newborn screening cohorts enrolled in comprehensive
care systems in the United States (published in 2004
and 2010), the United Kingdom (published in 2007),
and Brazil (published in 2014) indicated that mortality in the first five years of life was significantly lower
than in the 1978 Jamaican report, with the expectation
that 86% to 98% of children with SCD would live to
adulthood.2,6–9
However, not all recent research indicates similar
findings in SCD mortality. A study using data from
the National Center for Health Statistics’ (NCHS’s)
compressed mortality (CM) files, 1999 through 2006,
estimated the mean age at death for patients with SCD
to be 39 years in 2006.10 In that study, among the 483
SCD deaths in the United States reported during that
year, 9% occurred in those aged 20 years or younger
and 35% occurred in those older than 45 years of
age. A study using NCHS’s multiple cause of death
(MCOD) files, 1979 through 2005, to estimate age at
death and death rates similarly found median ages at

death among women and men with SCD to be 42 and
38 years, respectively.11
One important caveat to previous mortality studies
is that researchers relied on death certificate reporting of SCD10,11 or on populations seen at high-volume
hematology clinics.2–9 Studies based on death certificates assumed accurate and complete coding in the
death record, while the clinic-based studies may have
been biased to include the sickest SCD patients, who
are more likely to be seen at specialty care centers.
To address these limitations, we used data on SCD
patients from California and Georgia who were identified during the Registry and Surveillance System for
Hemoglobinopathies project and linked them to all
state death record files to estimate the all-cause mortality rate and mean and median ages at death for SCD
in these two states.12
METHODS
The National Institutes of Health-funded and Centers
for Disease Control and Prevention (CDC)-directed
Registry and Surveillance System for Hemoglobinopathies project collected and linked populationbased surveillance data from a variety of sources in
California and Georgia for 2004 through 2008.12 These
data sources included state administrative data and
newborn screening records, as well as case reports of
patients from hemoglobinopathy specialty treatment
centers. All administrative data sources used International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) codes, except for state death
record files, which used International Classification of
Diseases, 10th Revision (ICD-10) codes.13,14
Data collection: California
In California, data were requested from state newborn
screening (all SCD patients born 2000 through 2008);
vital records (state-based MCOD files, all deaths in 2004
through 2008); Office of Statewide Health Planning
and Development: inpatient files (all records 2004
through 2008) and emergency department files (all
records 2005 through 2008); Medi-Cal/Medicaid (all
individuals insured in 2004 through 2008 who had an
SCD ICD-9-CM code [282.41, 282.42, 282.6, 282.60,
282.61, 282.62, 282.63, 282.64, 282.68, 282.69]); hemoglobinopathy specialty treatment centers: Children’s
Hospital Los Angeles (all children and adults seen in
2004 through 2008 who had an SCD diagnosis) and
University of California San Francisco Benioff Children’s Hospital Oakland (all children and adults seen
in 2004 through 2008 who had an SCD diagnosis).
After cleaning, data for patients found in multiple

Public Health Reports / March–April 2016 / Volume 131

Sickle Cell Disease Mortality

datasets were linked by deterministic matching using
social security number and date of birth where sufficient data were available, or by probabilistic algorithm15 using weighted combinations of date of birth,
sex, geographic area, facility attended, and diagnosis
where sufficient data were unavailable. Details on data
used, linkage, and results are available elsewhere.12,16
Data collection: Georgia
In Georgia, data were requested from state newborn
screening (all SCD patients born 2004 through 2008);
vital records (state-based MCOD files, all deaths in 2004
through 2008); Georgia Hospital Association: inpatient
files (all records in 2004 through 2008) and emergency
department files (all records in 2004 through 2008);
Medicaid (all individuals insured in 2004 through
2008 who had an SCD ICD-9-CM code); Georgia’s
Children’s Health Insurance Program (all individuals
insured in 2004 through 2008 who had an SCD ICD9-CM code); Georgia’s State Health Benefit Plan (all
individuals insured in 2004 through 2008 who had an
SCD ICD-9-CM code); and hemoglobinopathy specialty
treatment centers: Georgia Comprehensive Sickle Cell
Center at Grady Memorial Hospital (all children and
adults seen in 2004 through 2008 who had an SCD
diagnosis), Georgia Health Sciences University (all
children and adults seen in 2004 through 2008 who
had an SCD diagnosis), and all three campuses of
Children’s Healthcare of Atlanta (all children seen in
2004 through 2008 who had an SCD diagnosis).
Few data sources included social security numbers
or Medicaid identification numbers consistently;
therefore, deterministic matching of patients was not
feasible for most datasets in Georgia. Each dataset was
de-duplicated and datasets were then matched, one at
a time, using a probabilistic algorithm that assigned
differing weights to identifying variables, such as date
of birth, patient’s name, mother’s name (for children),
sex, county, telephone number, and address. Details on
data used, linkage, and results are available elsewhere.12
Inclusion criteria
This study included patients (referred to as SCD
patients) who were reported by newborn screening
and/or one of the reporting hemoglobinopathy specialty treatment centers with a laboratory-confirmed
diagnosis (n=6,263). Patients with a combination
of two or more health-care encounters with SCD
ICD-9-CM codes and one or more expected SCD
treatments, procedures, or complications (n=5,880)
were also included.12,16 This study did not include individuals having one or more health-care encounters
with an SCD ICD-9-CM code but no evidence of an
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expected SCD treatment, procedure, or complication
(n517,642).
Mortality analyses
All SCD patients were linked to state-based MCOD
files for 2004 through 2008 by using social security
numbers or full names and dates of birth. All-cause
mortality rates for the SCD population were calculated
as the number of SCD patients who died from 2004
through 2008 in a given age group divided by the
total number of SCD patients in that age group during the same period. The result was then divided by
five for an annual average. For some SCD patients, the
linked death records did not include SCD as a cause
of death but otherwise met the inclusion criteria and
were included in these analyses. Conversely, deaths
in the state-based MCOD files that included SCD as a
cause of death, but did not fit our inclusion criteria,
are described separately and were not included in
calculations of mortality rates or age at death.
All-cause mortality rates for the African American
population and the general population in Georgia
and California for 2008 only were derived by using
CDC’s Wide-ranging Online Data for Epidemiologic
Research (WONDER) MCOD queries. 17 Data on
SCD-coded deaths were also queried from the NCHS
MCOD database and the NCHS CM database (also via
CDC WONDER) for California and Georgia for years
2004 through 2008, for comparison with published
SCD mortality surveillance reports and methods.10,11,17,18
NCHS MCOD files are related to the state-based
MCOD death files; both sets of files are derived from
death certificates, both allow for coding of up to 24
underlying and contributing causes of death, and the
methodology for coding is consistent across all states.
State-based MCOD files, however, have patient-level
data, include some identifiers, and are only offered
to researchers and public health agencies for analysis
under specific circumstances. NCHS MCOD files are
reported to the public as aggregated data. In contrast
with NCHS and state-based MCOD files, NCHS CM
data indicate only the reported underlying cause of
death and not contributing causes. As with the NCHS
MCOD files, NCHS CM data are reported publicly as
aggregate counts and rates and are not reviewable
as individual patients. Also of note, both the NCHS
MCOD and CM reports suppress results when a cell
size is ,10; therefore, information for some age groups
may be incomplete if fewer than 10 patients in that
age group died during the period of interest. We used
ICD-10 coding to identify patients with SCD from the
NCHS CM and NCHS MCOD files included in this
study (D57.0, D57.1, D57.2, D57.8).
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We calculated all-cause mortality rates for the SCD
population in the two states (deaths per 1,000 patients)
by age group at time of death, all-cause mortality rates
for the African American population (deaths per
1,000 population), and all-cause mortality rates for all
populations (deaths per 1,000 population) from both
states. We calculated mean, standard deviation (SD),
and median age at death by sex and overall. The data
analysis for by this study was generated using SAS®
version 9.3.19

1,000 population) in the youngest age group but rose
steadily compared with the all-cause African American
rates thereafter, until the oldest age group (Figure 1).
For SCD patients, the mean (SD) age of death was 43.4
years (16.8) for females (median: 43.5 years) and 40.8
years (17.0) for males (median: 41.9 years); the mean
age of death for all patients was 42.2 years (16.9) and
median age of death was 42.8 years.
Data from the NCHS CM files showed 297 patients
in Georgia and California with an underlying cause
of death of SCD in 2004 through 2008; data from the
NCHS MCOD files showed 513 patients with an underlying or contributing cause of death of SCD in 2004
through 2008; and data from population-based surveillance showed 615 SCD deaths in 2004 through 2008
(Figure 2). Sub-analysis of the NCHS data by age group
produced information on 258 deaths from the CM file
and 482 deaths from the MCOD file; these smaller
numbers resulted from the suppression of cells with
fewer than 10 deaths. The proportion of SCD deaths
in the older age groups identified through populationbased surveillance ($45 years of age: 276/615, 45%)
was larger than that identified by NCHS data (CM files:
95/297, 32%; MCOD files: 205/513, 40%). Deaths
among the oldest age groups ($65 years) occurred
in 53/615 (9%) of SCD patients identified through
population-based surveillance, 0/297 (0%) in the same

RESULTS
Of the 12,143 SCD patients identified through population-based surveillance in California and Georgia
in 2004 through 2008 and who met the inclusion
criteria for this study, 615 were linked to records in
state-based MCOD files. Among these 615 records,
143 were patients with known genotype and 472 were
patients with unknown genotype. Proportions among
age groups and sex were similar across the two states.
Among these 615 SCD deaths, 16% of deaths occurred
before 25 years of age and 45% of deaths occurred
after 44 years of age (Table).
All-cause mortality rates for the SCD population (1.5
deaths per 1,000 patients) were lower than the all-cause
mortality rates for African Americans (2.8 deaths per

Table. Number of deaths for sickle cell disease patients identified using 2004–2008 population-based surveillance
data, California and Georgia
California and Georgia
combined

Characteristic
Total
Age group (in years)
0–4
5–14
15–24
25–34
35–44
45–54
55–64
65–74
$75
Sexb
Male
Female

Number of
SCD patients

Number of
SCD deaths
(percent)a

12,143

615

1,738
2,686
2,435
1,986
1,496
1,097
474
164
67

13
18
68
101
139
142
81
32
21

5,512
6,630

California

Number of
SCD patients

Georgia

Number of
SCD deaths
(percent)a

5,135

327

(2)
(3)
(11)
(16)
(23)
(23)
(13)
(5)
(3)

746
1,096
979
781
656
524
236
83
34

8
10
36
46
72
79
45
19
12

289 (47)
325 (53)

2,337
2,798

Number of
SCD patients

Number of
SCD deaths
(percent)a

7,008

288

(2)
(3)
(11)
(14)
(22)
(24)
(14)
(6)
(4)

992
1,590
1,456
1,205
840
573
238
81
33

5
8
32
55
67
63
36
13
9

152 (46)
175 (54)

3,175
3,832

Combined
mortality
rate per
1,000 patients
per year
10.1

(2)
(3)
(11)
(19)
(23)
(22)
(13)
(4)
(3)

1.5
1.3
5.6
10.2
18.6
25.9
34.2
39.0
62.7

137 (48)
150 (52)

10.5
9.8

Column percentages may not total to 100 because of rounding.

a

b

One Georgia patient was missing information on sex.

SCD 5 sickle cell disease
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Figure 1. All-cause mortality rates for the sickle cell disease population identified through
population-based surveillance (2004 through 2008), the African American population (2008),a
and all populations (2008),a California and Georgia

Centers for Disease Control and Prevention (US), National Center for Health Statistics. Multiple cause of death 1999–2013 [cited 2015 Dec 15].
Available from: http://wonder.cdc.gov/mcd.html
a

age group in the NCHS CM files, and 13/513 (3%) in
the NCHS MCOD data.
Among the 615 SCD patients linked to statebased MCOD data, 352 (57%) had an underlying or
contributing cause of death coded as SCD, and the
remaining 263 (43%) did not have SCD listed as a cause
of death (Figure 3). In addition to the 615 state-based
MCOD death certificates linked to SCD patients, 155
deaths were found in the state-based MCOD data (84
in California, 71 in Georgia) with an SCD ICD-10 code
(excluding the code for sickle cell trait, D57.3), but
no other evidence of SCD in the linked data sources.
Among these 155 deaths were 81 deaths with an SCD
code as the underlying cause of death and 74 with an
SCD code as a contributing (but not underlying) cause
of death. This group had a mean (SD) age of death
of 45.0 years (17.8) and median age of death of 46.4
years; however, these 155 patients were not included in
the analyses because they did not meet the inclusion
criteria for our study.
DISCUSSION
This study was the first population-based SCD mortality
study in the United States in which the denominator
of patients with SCD was estimated from multiple and
diverse linked data sources.12 Our mortality rates were
similar to previous reports from the United States,

Jamaica, and United Kingdom.4,7,8,10,20–24 Our methodology for describing mortality in SCD identified more
deceased patients and a higher proportion of patients
living longer than did the methodologies in previous
reports.10,11 Our study identified 615 deaths among SCD
patients in California and Georgia in 2004 through
2008. Comparable NCHS CM data yielded 297 SCD
deaths during the same five years (48% of the deceased
SCD patients), whereas NCHS’s MCOD data yielded
83% of the deceased patient count. More importantly
for understanding SCD outcomes, we found the allcause mortality rate for the SCD population aged 5–74
years to be noticeably higher than all-cause mortality
rate for the African American population and the
all-cause mortality rate for the general population of
the same age. We also found a higher proportion of
SCD patients dying in the older age groups than did
previous research.
Methodologically, our approach had several
strengths over the previous research on SCD mortality.
First, certain biases may be introduced when estimating survival from clinic-based populations, even when
studied prospectively.2,3 Late entry, attrition, selection of
a potentially more symptomatic population of patients,
and better medical management are among a number
of limitations of this approach. Because we were able to
analyze SCD mortality using a population-based sample
of patients with SCD, our surveillance effort included
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not only the fraction of the patient population being
cared for by SCD experts, but also those who had care
outside of sickle cell centers or were without medical
homes or regular care providers.
Another challenge for previous studies was estimating the underlying prevalence of SCD in the population. Some researchers estimated it by using newborn
screening data or by basing it on a portion of the
total African American population.4,5 However, these
methods may not account for those not identified by
newborn screening or early mortality in patients with
SCD. Newborn screening was not instituted until the
1970s and did not become widespread in the United
States until the late 1980s,3 raising the potential for the
older population of patients to be underrepresented in
previous studies. Estimates based on newborn screening
data also do not include those who were born outside
of the United States.

Limitations
Although our study attempted to address many of
the limitations of previous reports, several limitations
remained. Only 23% of deceased SCD patients had a
laboratory-confirmed diagnosis of SCD and were followed in comprehensive SCD programs or identified
via newborn screening; however, we believe the remaining deceased individuals had a high probability of also
being true SCD patients. These 472 patients without a
laboratory-confirmed diagnosis were included as SCD
patients based on multiple SCD-coded encounters in
administrative datasets and relevant treatments, procedures, or complications that support the diagnosis;
nevertheless, they did not have a known genotype,
which limited the ability to determine mean and
median ages at death by disease type. They may also
differ significantly from the 143 SCD patients among
whom the SCD genotype was confirmed because of the

Figure 2. Number of deaths for sickle cell disease patients identified using NCHS’s compressed mortality reports
(2004–2008),a NCHS’s multiple cause of death reports (2004–2008),b and population-based surveillance data
(2004–2008), California and Georgia

Centers for Disease Control and Prevention (US), National Center for Health Statistics. Multiple cause of death 1999–2013 [cited 2015 Dec 15].
Available from: http://wonder.cdc.gov/mcd.html
a

Centers for Disease Control and Prevention (US), National Center for Health Statistics. Compressed mortality file 1999–2013 [cited 2015 Dec
15]. Available from: http://wonder.cdc.gov/cmf-icd10.html
b

NCHS 5 National Center for Health Statistics
MCOD 5 multiple cause of death
SCD 5 sickle cell disease
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Figure 3. Number of deaths for sickle cell disease patients identified using population-based surveillance data
(2004–2008), state-based multiple cause of death (MCOD) data files (2004–2008), NCHS’s multiple cause of death
reports (2004–2008),a and NCHS’s compressed mortality reports (2004–2008),b California and Georgia

Population-based
surveillance data
(n512,143)

State-based
MCOD data
(n51,513,507)

NCHS
MCOD data
(n51,513,507)

PBS patients in statebased MCOD data
(n5615)

State-based MCOD
patients not linked to
PBS (n5155)

SCD cause
of death
(n5513)

With SCD underlying
cause of death
(n5216)

With SCD underlying
cause of death
(n581)

With SCD underlying
cause of death
(n5297)

With SCD
contributing cause
of death (n5136)

With SCD
contributing cause
of death (n574)

With SCD
contributing cause
of death (n5216)

NCHS compressed
mortality data
(n51,513,507)

With SCD underlying
cause of death
(n5297)

With no SCD
cause of death
(n5263)

Centers for Disease Control and Prevention (US), National Center for Health Statistics. Multiple cause of death 1999–2013 [cited 2015 Dec 15].
Available from: http://wonder.cdc.gov/mcd.html
a

Centers for Disease Control and Prevention (US), National Center for Health Statistics. Compressed mortality file 1999–2013 [cited 2015 Dec
15]. Available from: http://wonder.cdc.gov/cmf-icd10.html
b

PBS 5 population-based surveillance
MCOD 5 multiple cause of death
NCHS 5 National Center for Health Statistics
SCD 5 sickle cell disease

underlying differences in the ways these two groups
were identified. The patients with confirmed genotypes
were from newborn screening data or from specialty
SCD programs, so they were likely younger than the
general SCD population, and/or received comprehensive care, and/or were referred to a specialty center
because of the severity of their disease.
Furthermore, although validation efforts used in
the Registry and Surveillance System for Hemoglobinopathies study suggest a small error rate in using this
approach of combining diagnosis and complications
to identify patients,25 and our results were similar to

other studies that examined the accuracy of using
diagnosis codes for SCD patient finding,26 patients
who were older and/or living with milder disease may
be underrepresented in these data. Consequently, the
normalization of the mortality rate among the oldest
group of SCD patients may result from the underlying
patient population’s small size (n567), a high proportion of older patients who did not actually have SCD,
yet met our study’s inclusion criteria, and/or an older
population more likely to have milder disease and more
likely to die from non-SCD-related causes. Furthermore, our methods did not allow us to d
 etermine if
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identified patients moved out of California or Georgia
during the five-year period and who, if so, should not
have been included in the denominator for mortality
calculations. Additionally, it is impossible to derive
measures of central tendency from NCHS data (either
the MCOD or CM files) because deaths are aggregated
by age group; we therefore compared the means and
medians reported in the earlier studies that are from
earlier years of collected data and not specific to only
these two states.4,5 Finally, this analysis includes only
the 5% of the Registry and Surveillance System for
Hemoglobinopathies patients who had died during a
five-year period of observation from 2004 through 2008.
CONCLUSION
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